TABLE 1.

Demographic data and clinical features of participants in the CVA negative diagnosis group and CVA positive diagnosis group.

Characteristics and variables	CVA negative diagnosis group (n = 98)	CVA positive diagnosis group (n = 42)	P-value
Age(years)¶	45.50 [28.25]	42.00 [29.50]	0.622
Gender, male (n,%)	34 (34.69%)	12 (28.57%)	0.480
Height (cm)¶	162.50 [13.00]	165.00 [14.00]	0.980
Weight (kg)¶	60.00 [13.00]	62.00 [19.25]	0.539
BMI (kg/m2)¶	22.49 [3.70]	22.81 [4.72]	0.356
Former smoker (n,%)	11 (11.22%)	4 (9.52%)	0.766
Symptom duration (months)¶	7.00 [10.25]	9.50 [9.50]	0.221
Symptom recovery time (days)¶	12.00 [15.25]	7.00 [5.50]	0.001
VAS1¶	75.00 [15.00]	80.00 [10.00]	0.001
ΔVAS¶	45.00 [47.50]	65.00 [16.30]	<0.001
FENO (ppb)¶	21.50 [22.25]	33.00 [32.25]	0.010
WBC (*109/L)¶	6.11 [2.49]	6.73 [2.06]	0.465
EOS%¶	1.90 [1.65]	1.95 [2.55]	0.742
EOS (*109/L)¶	0.12 [0.12]	0.13 [0.20]	0.552
FVC%pred§	100.20 ± 11.41	95.01 ± 13.34	0.021
FEV1%pred¶	97.00 [15.37]	87.05 [17.42]	<0.001
FEV1/FVC	0.82 ± 0.06	0.79 ± 0.05	0.021
PEF%pred§	97.00 ± 14.33	86.33 ± 18.68	<0.001
FEF25%pred§	95.77 ± 18.57	81.58 ± 18.00	<0.001
FEF50%pred§	80.10 ± 22.47	63.22 ± 14.19	<0.001
FEF75%pred¶	62.86 [32.98]	49.96 [33.97]	0.003
FEF25–75%pred§	75.54 ± 21.97	59.63 ± 16.91	<0.001
ΔFVC¶	50.00 [112.50]	120.00 [197.50]	0.001
ΔFEV1¶	100.00 [145.00]	185.00 [115.00]	<0.001
ΔFEV1/FVC	0.02 [0.04]	0.03 [0.06]	0.039
ΔPEF¶	255.00 [780.00]	350.00 [880.00]	0.792
ΔFEF25¶	265.00 [817.50]	450.00 [1015.00]	0.168
ΔFEF50¶	340.00 [530.00]	525.00 [507.50]	0.127
ΔFEF75¶	140.00 [280.00]	260.00 [250.00]	0.023
ΔFEF25–75¶	300.00 [395.00]	475.00 [397.50]	0.007
ΔFVC%¶	1.39 [3.87]	3.44 [7.69]	0.001
ΔFEV1%¶	3.77 [4.76]	7.99 [3.67]	<0.001
ΔPEF%¶	3.89 [11.42]	6.45 [15.22]	0.588
ΔFEF25%¶	5.06 [13.96]	10.75 [21.65]	0.077
ΔFEF50%§	12.94 ± 14.53	19.60 ± 18.87	0.025
ΔFEF75%¶	13.91 [31.98]	32.84 [43.87]	0.002
ΔFEF25–75%¶	12.63 [18.68]	23.24 [19.41]	<0.001

FENO, fractional exhaled nitric oxide; VAS₁, visual analog scale score at the first visit; ΔVAS, improvement of VAS from baseline to 4 weeks of treatment; WBC, white blood cells; EOS, eosinophils; BMI, body mass index; FVC, forced vital capacity; FEV₁, forced expiratory volume in 1 s; PEF, peak expiratory flow; FEF₂₅, forced expiratory flow at 25% of forced vital capacity; FEF₅₀, forced expiratory flow at 50% of forced vital capacity; FEF₇₅, forced expiratory flow at 75% of forced vital capacity; FEF_25–75, forced expiratory flow at 25% to 75% of forced vital capacity; %pred, the actual measured value of spirometric indices as a percentage of the predicted value. Δ, increase in spirometric indices in BDR; Δ%, spirometric indices %, increase in spirometric indices as a percentage of the baseline value. ^§Mean ± standard deviation values; ^¶Median [IQR] values; Statistical significance is shown by bold font.